캐나다의 경우 타업체 보다 몇 개월 빠르다고 그렇게 장담하더만
셀트리온 역시 오리지날사와 특허 합의끝났다.
셀트리온에서 공식 발표하는 순간 너네들 퍼스트 무버는 끝났다.
삼천당 고유특허로 문제없다더만, 타 경쟁업체 역시 쉽게 뚫네?ㅎㅎㅎ
On January 15, 2024, the Company and Bayer Inc. filed patent infringement lawsuits against Celltrion, Inc., Celltrion Healthcare Co, Ltd., Celltrion Pharma Inc., and Celltrion Healthcare Canada Ltd. in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept 2 mg biosimilar would directly or indirectly infringe one or more claims of the 510 Patent, the 276 Patent, the 495 Patent, the 768 Patent,the 193 Patent, and the 315 Patent. On July 2, 2024, the Company, Bayer Inc., Bayer Healthcare LLC, and Celltrion, Inc. entered into a settlement agreement concerning these patent infringement lawsuits, pursuant to which each such lawsuit has been dismissed and Celltrion is generally precluded from launching its aflibercept 2 mg biosimilar product in Canada until July 1, 2025.
이거 리제네론 8월 2일 발표한 사업보고서에 소송 관련된 공식 내용이야~
알아서 잘 판단하길~